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Anaplastic large cell lymphoma, (ALCL) first described
by Stein et al. in 1985,1 is a high-grade lymphoma,
accounting for 10% of childhood lymphomas. It is char-
acterized by a proliferation of CD30-positive large lym-
phoid cells with pleomorphic nuclei and single or multi-
ple prominent nucleoli. Lineage-specific antigens show a
T-cell or null-cell phenotype.2,3 In approximately 60% of
ALCL, ALK expression can be detected by immunohisto-
chemistry. The expression of ALK is due to chromosomal
translocations involving the ALK gene and different part-
ner genes.4-7 The translocation t(2;5)(p23;q35) is found in
up to 75% of ALK + ALCL, resulting in the NPM-ALK
chimeric protein.8,9 ALK-positive ALCL occurs predomi-
nantly in children and young adults. It has a broad mor-
phological spectrum and different morphological variants
have been described.10 Up to 80% of pediatric patients
with ALCL can be cured with multi-agent chemothera-
peutic regimens. Patients who suffer a relapse have an
85% chance of achieving a second complete remission,
but 40% of them will have a second relapse. Disease free
survival (DFS) at 3 years after the first relapse was report-
ed to be 28% for patients with early relapse (<12 months
after first diagnosis) versus 68% for patients with late
relapse (>12 months after diagnosis). Second and further
relapses occur in both groups. Patients resistant to
chemotherapy or suffering from early relapse have a poor
prognosis.11,12 Autologous SCT (ASCT) seems to have a
place in the treatment of patients with ALCL as consoli-
dation therapy or in patients who achieved a second
complete remission, but prospective studies are needed
to confirm the advantage of ASCT versus conventional
chemotherapy.12 Allogeneic HSCT has been proposed as
therapeutic option in patients with relapse of ALCL.13
Clinical reports of such patients are rare, only two chil-
dren were described who received allogeneic bone mar-
row transplantation and who remain in complete remis-
sion 56 and 40 months after the transplant (14). We
report the clinical history, therapy and outcome after allo-
geneic HSCT of a girl with early relapse of ALCL.
Case report
An 8 year-old girl presented in March 2003 with high
fever, skin rash, hepatosplenomegaly and enlargement of
the lymph nodes. Computer tomography showed patho-
logical lymph nodes bilateral in the neck, mediastinum,
mesenterium and retroperitoneum. Histological examina-
tion of biopsies from a cervical lymph node and a skin
lesion led to the diagnosis of ALCL. Bone marrow (BM)
trephine biopsies, examination of cerebrospinal liquid
and Tc99 bone scan were negative. Histological and
immunohistochemical studies showed the presence of T-
cell marker CD3 and typical markers for ALCL: CD30,
EMA and ALK. Karyotyping of the tumor cells demon-
strated the presence of the t(2;5) translocation.
According to the St. Jude classification, this girl had a
stage III ALCL. Informed consent was obtained and she
was enrolled in the European ALCL-99 high-risk study
(Table 1). There was a prompt clinical response to thera-
py and a complete evaluation performed after 3 cycles of
chemotherapy could not reveal residual tumor. At admis-
sion for the fourth course, she presented with fever and
chemotherapy was delayed for one week. Soon a relapse
became evident, with clinical enlargement of lymph
nodes and reappearance of skin lesions. Relapse of ALCL
was histologically confirmed. Staging examinations
showed again mediastinal and abdominal tumor masses.
BM and central nervous system examination was nega-
tive for tumor cells. 
Reinduction treatment was given according to a proto-
col draft of the EICNHL (European Intergroup co-opera-
tion on Childhood Non-Hodgkin-Lymphoma) for
patients with relapse of ALCL (Table 2). 
After the first reinduction course, immediate clinical
response was seen and an allogeneic hematopoietic stem
cell transplantation (HSCT) with a matched unrelated
donor (MUD) was scheduled, since there was no sibling
donor available. A few days before the start of the condi-
tioning regimen a fast growing cervical mass was indicative
for second relapse.  The lymph node regressed after one
injection of vincristin and corticosteroids for 3 days. The
patient then received the planned conditioning regimen.
Preparative therapy consisted of Thiotepa (10 mg/kg)
at day-7, VP16 (40 mg/kg) at day - 6 and TBI (12 Gy total
dose in 2×2 Gy fractions/day) at days - 4, - 3, - 2. A total
of 6×108/kg nuclear cells were infused with CD34+ frac-
tion of 4,6×106/kg. Medications to prevent graft versus
host disease (GvHD) were ATG (14 mg/kg), Cyclosporine
A and Methotrexate (3×10mg/m2). The MUD-HSCT was
well tolerated, engraftment of white blood cells was seen
at day +26, platelets engraftment occurred at day + 23.
Because the patient had no signs of GvHD, CsA was
tapered off and stopped on day +120. Complete evalua-
tion of tumor parameters and imaging studies performed
3, 6, 9 and 12 months after HSCT showed no signs of
residual masses. DNA examination of blood and bone
marrow demonstrated full donor chimerism. 
For this child, with a well-documented early relapse of
ALK+ ALCL, a MUD-HSCT was the last option of cure.
Now, more than 18 months after MUD-HSCT, she
remains in continuous complete remission (CR). She is
going to school again and enjoying a very good quality of
life. There are no signs of GvHD and until now no trans-
plant- related complications have occurred. 
Discussion
This child with an early relapse of ALK+ ALCL, has
remained in remission after matched unrelated stem cell
transplant for more than one year, with full donor
chimerism. Autologous stem cell transplantation is effica-
cious in some patients with relapse of ALCL, but second
relapses after high dose therapy are not a rare event.
Brugières et al. reported second relapse in 5 out of 15
patients transplanted in CR2 at a median time of 16
months, all three patients who underwent autologous
ASCT in partial remission died from disease progression
within 10 months, whereas 2 out of 3 patients treated in
CR3 relapsed again.11 The role of allogeneic HSCT
remains to be determined.
We postulate that in our patient a graft versus lym-
phoma (GvL) effect might play a role in the sustained
remission after allogeneic HSCT. In accordance with this
hypothesis Verdonck et al. reported favorable outcomes
after allogeneic HSCT in patients with resistant and
recurrent low-grade lymphomas.15 It is well known that
there is a higher incidence of lymphomas in AIDS
patients and in patients with other immune deficiencies.16
These observations indicate that the immune system
plays a pivotal role in the pathogenesis of such malignan-
cies. Our patient did not develop GvHD, but GVL can
occur in the absence of clinical GVHD.17,18
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Conclusion
Allogeneic HSCT might be a valid option in the treat-
ment of patients with early relapse of ALCL. As second
and subsequent relapses occur after autologous stem cell
transplantation in ALCL, we hypothesize that a graft ver-
sus lymphoma effect effect and not only the high-dose
chemotherapy might explain the sustained complete
remission in this case, even when no signs of GvHD are
present. Prolonged follow-up and more patients are
needed to determine the benefits of allogeneic stem cell
transplantation in patients with resistant disease or early
relapse of ALCL. 
Genevieve Laureys, Catharina Dhooge, Els Vandecruys, Pascale
De Paepe, Yves Benoit
Dept. of Pediatric Hematology & Oncology, Ghent University
Hospital, 5K6, Ghent, Belgium. 
References
1. Stein H, Mason DY, Gerdes J, O’Connor N, Wainscoat J,
Pallesen G, et al. The expression of the Hodgkins-disease asso-
ciated antigen Ki-1 in reactive and neoplastic lymphoid-tissue:
evidence that Reed-Sternberg cells and histiocytic malignan-
cies are derived from activated lymphoid cells. Blood, 66: 848,
1985.
2. Delsol G, Al Saati T, Gatter C, Gerdes J, Schwarting R,
Caveriviere P, et al. Coexpression of epithelial membrane anti-
gen (EMA), Ki-1 and interleukin-2 receptor by anaplastic large
cell lymphomas: diagnostic value in so-called malignant histi-
ocytosis. Am J Pathol, 130: 59, 1988.
3. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML,
et al. A revised European-American classification of lymphoid
neoplasms: A proposal from the International Lymphoma
Study Group. Blood, 84: 1361, 1994.
4. Foss H, Anagnostopoulos I, Araujo I, Assaf C, Demel G,
Kummer J, et al. Anaplastic large-cell lymphomas of T-cell and
null-cell phenotype express cytotoxic molecules. Blood, 88:
4005, 1996.
5. Rimokh R, Magaud JP, Berger F, Samarut J, Coiffier B, Germain
D, et al. A translocation involving a specific breakpoint (q35)
on chromosome 5 is characteristic of anaplastic large cell lym-
phoma (Ki-1 lymphoma). British Journal of Haematology, 71:
31, 1989. 
6. Mason D, Bastard C, Rimokh R, Dastugue N, Huret J,
Kristoffersson U, et al CD30-positive large cell lymphomas
(‘Ki-1 lymphoma’) are associated with a chromosomal translo-
cation involving 5q35. British Journal of Haematology, 74: 161,
1990.
7. Lamant L, Meggetto F, Al Saati T, Brugieres L, de Paillerets B,
Dastugue N, et al. High incidence of the t(2;5)(p23;q35)
translocation in anaplastic large cell lymphoma and its lack of
detection in Hodgkin’s disease. Comparison of cytogenetic
analysis, reverse transcriptase-polymerase chain reaction and
P-80 immunostaining. Blood, 87: 284, 1996.
8. Shiota M, Fujimoto J, Takenaga M, Satoh H, Ichinohasama R,
Abe M, et al. Diagnosis of t(2;5)(p23;q35)-associated Ki-1
Lymphoma with immunohistochemistry. Blood, 84: 3648,
1994.
9. Shiota M, Nakamura S, Ichinohasama R, Abe M, Akagi T,
Takeshita M, et al. Anaplastic large cell lymphomas expressing
the novel chimeric protein P80 (NPM/ALK): a distinct
clinopathological entity. Blood, 86: 1954, 1995.
10. Jaffe ES, Harris NL, Stein H, Vardiman JW. (Eds.): World
Health Organization Classification of Tumors. Pathology and
Genetics of Tumours of Haematopoietic and Lymphoid
Tissues. Lyon, France: IARC Press,  2001:230-235. 
11 Brugières L, Quartier P, Le Deley MC, Pacquement H, Perel Y,
Bergeron C, et al. Relapses of childhood anaplastic large-cell
lymphoma: Treatment results in a series of 41 children - A
report from the French Society of Pediatric Oncology. Ann
Oncol., 11: 53, 2000.
12. Fanin R, Ruiz de Elvira MC, Sperotto A, Baccarani M,
Goldstone A. Autologous stem cell transplantation for T and
null cell CD30-positive anaplastic large cell lymphoma: analy-
sis of 64 adult and paediatric cases reported to the European
Group for Blood and Marrow Transplantation (EBMT). Bone
Marrow Transplant,  23: 437, 1999.
13. Liso A, Tiacci E, Binazzi R, Pulford K, Benedetti R, Carotti A,
et al. Haploidentical peripheral-blood stem-cell transplantation
for ALK-positive anaplastic large-cell lymphoma. The Lancet
Oncol., 5: 127, 2004.
14. Chakravarti V, Kamani NR, Bayever E, Lange B, Herzog P,
Sanders JE et al. Bone-marrow transplantation for childhood
Ki-1 lymphoma. J Clin Oncol., 8: 657, 1990.
15. Verdonck LF, Dekker AW, Lokhorst HM, Petersen EJ,
Nieuwenhuis HK. Allogeneic versus autologous bone marrow
transplantation for refractory and recurrent low-grade non-
Hodgkin’s lymphoma. Blood,  90: 4201, 1997.
16. Levine A. Lymphoma complicating immunodeficiency disor-
ders. Ann Oncol., 5: S29-S35, 1994.
17. MacKinnon S, Papadopoulos EB, Carabasi MH, Reich L,
Collins NH, Boulad F, et al. Adoptive immunotherapy evaluat-
ing escalating doses of donor leukocytes for relapse of chronic
myeloid-leukemia after bone-marrow transplantation: separa-
tion of graft-versus leukemia responses from graft-versus- host
disease. Blood, 86: 1261, 1995.
18. Barret AJ, Mavroudis D, Tisdale J, Molldrem J, Clave E,
Dunbar C, et al. T cell-depleted bone marrow transplantation
and delayed T cell add-back to control acute GVHD and con-
serve a graft-versus-leukemia effect. Bone Marrow Transplant,
21: 543, 1998.E-mail: victoria.bordon@belgacom.net
G. Laureys et al.
| 56 | haematologica/the hematology journal | 2005; 90(online)
